SEC Company Response from NORTHWEST BIOTHERAPEUTICS INC (NWBO) (CIK 0001072379) (NWBO) — Feb 4, 2013
NORTHWEST BIOTHERAPEUTICS INC (NWBO) (CIK 0001072379)
Date: Feb. 4, 2013 · CIK: 0001072379 · Accession: 0001144204-13-005717
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-185898
Letter
Northwest Biotherapeutics Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
February 4, 2013
VIA EDGAR
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Austin Stephenson
Re: Northwest Biotherapeutics, Inc.
Registration Statement on Form S-3
File No. 333-185898
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Northwest Biotherapeutics,, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4 p.m., Eastern Standard Time, on Tuesday, February 5, 2013, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
NORTHWEST BIOTHERAPEUTICS, INC.
By: /s/ Linda F. Powers
Name: Linda F. Powers
Title: Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm Northwest Biotherapeutics Inc. 4800 Montgomery Lane, Suite 800 Bethesda, MD 20814 February 4, 2013 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Austin Stephenson Re: Northwest Biotherapeutics, Inc. Registration Statement on Form S-3 File No. 333-185898 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Northwest Biotherapeutics,, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4 p.m., Eastern Standard Time, on Tuesday, February 5, 2013, or as soon thereafter as possible. The Company acknowledges that: 1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. NORTHWEST BIOTHERAPEUTICS, INC. By: /s/ Linda F. Powers Name: Linda F. Powers Title: Chief Executive Officer